SI-BONE, Inc.

NASDAQ:SIBN

Medical - Devices

Healthcare
$23.54 +3.45%

+$0.53 today

Market cap
$1.06B
Beta
0.70
P/E (TTM)
-41.4
EPS (TTM)
-$0.38
52W Low $11.48High $21.89

Volume 1.12M

Average 0.68M

SIBN Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

SI-BONE, Inc.NASDAQ: SIBN

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit grows, but more slowly than its trailing trend

Q1 FY2026 gross profit of $41.94M rose 11.3% year over year, behind the +17.3% change in trailing-twelve-month gross profit. Sequentially, it fell 5.8% from the prior quarter. Over 3 fiscal years it compounded at +20.8% a year.

Context

  • Gross profit amounted to 79.6% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +11.3% toward the trailing-twelve-month pace of +17.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$41.94M-5.8% QoQ
Last fiscal yearDec 2025
$159.88M+21.0% YoY
LTMMar 2026
$164.13M+17.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.3%——
1 year+21.0%——
3-year CAGR+20.8%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
159.88M USD
Year-over-year change
+21.0%
4-year CAGR
+19.0%

Gross Profit vs competitors

How SIBN compares with its peers on the latest reported figures

  • SIBN's LTM Mar 2026 gross profit of $164.13M is the lowest of the 6 companies compared; the peer median is $2.16B.
  • Its year-over-year change of +17.3% is the 2nd highest of 6, against a peer median of +12.4%.
  • Gross profit amounts to 79.6% of revenue for SIBN, versus a peer median of 65.3%.
SIBN Competitors Peer median
Gross Profit for SIBN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYKStryker CorporationLTM Jun 2026$16.84B +12.4%+13.3%65.2%
SNNSmith & Nephew plcFY2025$4.21B +3.1%+4.4%68.3%
GMEDGlobus Medical, Inc.LTM Jun 2026$2.16B +30.8%+37.7%68.5%
CNMDCONMED CorporationLTM Mar 2026$735.25M +0.9%+8.3%53.6%
ATECAlphatec Holdings, Inc.LTM Mar 2026$514.13M +16.1%+31.7%65.3%
SIBNSI-BONE, Inc.LTM Mar 2026$164.13M +17.3%+20.8%79.6%
Peer median (excluding SIBN) $2.16B+12.4%+13.3%65.3%

Competitors are the stored peer set for SIBN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue90.15M106.41M138.89M167.18M200.93M
Cost of Revenue10.43M15.71M29.47M35.06M41.05M
Gross Profit79.72M90.7M109.42M132.12M159.88M
Gross Margin88.4%85.2%78.8%79.0%79.6%
Research & Development12.44M13.63M15.03M16.56M17.45M
Selling, General & Admin118.95M136.69M141.32M150.81M164.76M
Operating Expenses131.39M150.31M156.35M167.37M182.21M
Depreciation & Amortization2.09M3.45M5.43M4.38M2.72M
EBITDA(50.97M)(54.99M)(34.45M)(23.09M)(10.91M)
EBITDA Margin-56.5%-51.7%-24.8%-13.8%-5.4%
Operating Income(51.67M)(59.61M)(46.93M)(35.25M)(22.33M)
Operating Margin-57.3%-56.0%-33.8%-21.1%-11.1%
Interest Income186K1.3M6.92M7.85M6.07M
Interest Expense5.37M2.82M3.46M3.44M5.28M
Other Income / Expenses(4.9M)(1.65M)3.6M4.34M3.42M
Income Before Tax(56.57M)(61.26M)(43.34M)(30.91M)(18.91M)
Pre-Tax Margin-62.8%-57.6%-31.2%-18.5%-9.4%
Income Tax Expense00000
Net Income(56.57M)(61.26M)(43.34M)(30.91M)(18.91M)
Net Margin-62.8%-57.6%-31.2%-18.5%-9.4%
EPS (Basic)(1.71)(1.79)(1.13)(0.75)(0.44)
EPS (Diluted)(1.71)(1.79)(1.13)(0.75)(0.44)
Weighted Avg Shares33.15M34.2M38.43M41.47M43.51M
Weighted Avg Shares (Diluted)33.15M34.2M38.43M41.47M43.51M

SI-BONE, Inc.

NASDAQ:SIBN

Intrinsic Alpha fair value

Locked

Current Price

$23.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.